- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Cibinqo® | compound 25 [PMID: 29298069] | PF-04965842 | PF04965842
abrocitinib is an approved drug (UK, Japan & EMA (2021), FDA (2022))
Compound class: Synthetic organic
Comment: Abrocitinib (PF-04965842) is a JAK inhibitor . X-ray crystal structures of PF-04965842 bound to both JAK1 and JAK2 have been deposited with the Protein DataBank (accession IDs 6BBU and 6BBV respectively). We used the SMILES string supplied with the article in which the structure was declared  to generate our representation of the chemical structure. The IUPAC name in abrocitinib's INN record resolves to the same StdInChIKey as our structure. PubChem CID 78323835 represents the structure without specified stereochemistry.
The JAKs are immunokinases that are molecular targets of therapeutics which are used in the treatment of immune-mediated diseases.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Abrocitinib (PF-04965842) is a JAK1-selective inhibitor that was advanced to clinical trial for the treatment of autoimmune diseases [1,4]. PF-04965842 exhibits 28-fold selectivity over JAK2, >340-fold over JAK3, and 43-fold over TYK2 at 1 mM ATP, and it shows a favourable selectivity profile over the broader kinome. It was approved for clinical use in 2021, by regulatory agencies in the UK, EU and Japan.|
|Approved drug for AD, which mediates immune suppression by inhibiting activity of the immunokinase JAK1.|